Background: Treatment of breast carcinoma MCF7cells with estradiol led to induction of a new 27 kDa protein, the cDNA was later cloned and identified as p27. This highly hydrophobic protein of 122 amino acids has 33% over all sequence similarity to the product of the 6-16 gene, that is induced by alfa/beta type interferons. It has been shown that p27is transcriptionaly induced by interferon alfa in various human cell lines. The induction induced by interferon alfa is independent of the presence of estradiol receptors on the cells. High levels of p27 mRNA, detected by Northern blotting, was found in 50% of the primary breast carcinoma cells, suggesting p27 can be a diagnostic marker for breast carcinoma detection. Examination of p27 expression by in situ hybridization in p27 over expressing tumors suggest that p27 gene is localized in cancer cells and some times also in fibroblastic cells of tumor stroma. IFI27 mRNA expression is highly up-regulated in lesional psoriatic epidermis and in non-lesional keratinocytes. It was also expressed in lichen planus, chronic eczema, cutaneous squamous cell cancers, and during normal wound repair when IFI27 was found in the proliferating subpopulation of keratinocytes. P27 Further studies are now necessary to elucidate the cause of p27 gene overexpression in breast carcinoma and in particular to determine whether it corresponds to chromosomal rearrangements in the 14q32 region and/or to induction by interferons of the alpha/beta type. P27 protein is highly hydrophobic, containing 2 trans-membrane spanning regions localized on human chromosome in band q32. The apparent molecular weight of IFI27 is 26-29 kDa on reduced SDS-PAGE. IFI induced proteins like P27 and P16 genes have also showed potential targets for anti-angiogenic therapy employing INFs.
Description: Rabbit polyclonal to IFI27
Immunogen: KLH conjugated synthetic peptide derived from IFI27
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 11 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
